Trials / Completed
CompletedNCT01017666
BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to understand whether BIIB014 has potential to affect how certain drugs are broken down by the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB014 | BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d |
| DRUG | Placebo | Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-06-02
- Completion
- 2010-06-02
- First posted
- 2009-11-20
- Last updated
- 2023-08-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01017666. Inclusion in this directory is not an endorsement.